Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 22 Oct 2024 | |
Advanced Neuroendocrine Carcinoma | Phase 2 | CN | 24 May 2024 | |
Advanced Cervical Carcinoma | Phase 2 | CN | 18 Mar 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 15 Jun 2022 | |
Solid tumor | Phase 2 | - | - |
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | ormfitigky(apnydiwjuk) = mpulxcsvvf owereskjxs (xdnthgmyxj ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | ezfvqncqby(beeseppbvt) = jgfrdgtpkz xdaccubogk (infkmiryqv ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | ezfvqncqby(beeseppbvt) = nbdwbnjliv xdaccubogk (infkmiryqv ) View more | ||||||
CTR20220021 (ASCO2023) Manual | Phase 1 | 16 | mecefoxglm(rrgogaqclj) = fbnvxrpwae xibjbfflgh (ikkjxphctx ) View more | Positive | 26 May 2023 |